Introduction
There is reasonable consensus that both humoral and T-cell responses will be required for an effective HIV vaccine [1] [2] [3] [4] , and vaccine candidates designed to elicit these responses have undergone efficacy trials. Two trials (Step/Phambili) tested an adenovirus serotype-5 (Ad5) vector encoding HIV-1 Gag/Pol/Nef (MRKAd5 HIV-1) designed to induce T cells to reduce viremia [5] [6] [7] . HVTN505 trial employed DNA-prime and Ad5-boost encoding Gag/Pol/Nef/Env [Virus Research Centre (VRC DNA/Ad5)], designed to elicit T cells and antibody [8] . RV144 trial tested a canarypox vector encoding Gag/Pol/Env (ALVAC-HIV) and gp120 protein-boost (AIDSVAX) designed to elicit T cells and antibody [9] . IFNg enzyme-linked immunospot (ELISpot) and flow cytometry assays demonstrated that both Ad5-based regimens are immunogenic, eliciting HIV-1-specific T cells in 70-80% of volunteers, which comprised both CD4 þ and CD8 þ polyfunctional T cells [6, [10] [11] [12] . However, these regimens tested in efficacy trials failed to protect against infection with limited impact on viremia in vaccinees infected subsequently [5] [6] [7] [8] , although T-cell responses to three or more Gag peptides in infected STEP vaccinees were associated with half-log lower viremia, compared with volunteers without Gag responses [13, 14] . The ALVAC/AIDSVAX regimen elicited CTL responses in 24% of vaccinees with binding and neutralizing antibody responses in 100 and 98% of volunteers, respectively [15] and demonstrated a 31.2% reduction in HIV acquisition, the most plausible correlate of protection being antibody-based [16] .
Despite the lack of efficacy of vaccine candidates designed to elicit T cells, there is ample evidence that T cells, in particular CD8 þ T cells, can control viral replication in vivo in both HIV-1 [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] and SIV infection, including vaccinated SIV-challenged nonhuman primates (NHP) [31] [32] [33] [34] [35] . The induction of broadly cross-reactive antiviral T cells is likely to be a crucial facet of efficacious vaccines, complementing humoral responses containing virus at the infection site.
ELISpot and flow cytometry assays, commonly employed to assess immunogenicity of vaccine candidates, measure cytokine production by T cells, in response to exogenous synthetic HIV peptides, functions that do not necessarily mediate direct inhibition of viral replication [36] [37] [38] and did not predict vaccine efficacy. The present report addressed whether CD8 þ T cells elicited in phase I/II trials of the MRKAd5 HIV-1, VRC DNA/Ad5 and ALVAC/AIDSVAX regimens mediate direct antiviral function by inhibition of HIV-1 replication in an in-vitro viral inhibition assay (VIA). Vaccine candidate HIV-1 gene insert-matched and mismatched HIV-1 isolates were tested, including transmitted/founder (T/F) viruses responsible for establishing infection [39] . Such assays would allow CD8 þ T cells to recognize naturally processed HIV-1 epitopes in infected CD4 þ T cells and correlate with virus control in humans [40] [41] [42] [43] [44] [45] and protection in NHP [32, 35] . Our initial qualification studies [43] in HIV-1-infected volunteers demonstrated a significant negative correlation of lower plasma viral load (pVL) and virus inhibition, with no correlation between IFNg ELISpot magnitude and pVL. Therefore, as a benchmark, the breadth of any inhibition elicited by vaccination was compared with that of HIV-1-infected volunteers demonstrating some natural control of HIV-1 replication in-vivo, evidenced by lower pVL (<10 000/ml) in the absence of antiretroviral therapy.
Methods

Volunteers
Frozen peripheral blood mononuclear cells (PBMC) were obtained from phase I/II clinical trials HVTN 071 (MRKAd5 HIV-1 regimen), V001 (VRC DNA/Ad5 regimen) and RV135 (ALVAC/AIDSVAX regimen) ( Table 1) . Samples were obtained from 16 antiretroviral-naive chronically HIV-1-infected volunteers from Chelsea and Westminster Hospital, London, UK and from HIV-1-uninfected South African blood transfusion volunteers. HIV-1-infected volunteers were selected with pVL less than 10 000 copies/ml (median 1265, range . Median CD4 þ cell count was 628 (range 247-1249). PBMC were isolated by density centrifugation, frozen at 10 million per vial in 10% dimethylsulphoxide/90% heat-inactivated fetal calf serum (HIFCS) (Sigma, Poole, Dorset, UK) and stored in vapour phase liquid nitrogen [47] . For all studies, informed consent and local ethical approval were obtained.
Viruses RV135 and HIV-1-infected volunteers' samples were tested in VIA with HIV-1 IIIB and CRF01_AE CM235 isolates, the latter provided by Victoria Polonis, Walter Reed Army Institute of Research, USA. For other vaccinees and HIV-1-infected volunteers, VIA was applied using the following six HIV-1 isolates (Genbank accession numbers where known and subtype); IIIB (HXB2 K03455, B), ELI (K03454, A/D) and 97ZA012 (AF286227, C) provided by the NIH AIDS Research and Reference Reagent Program. Virus stocks of T/F isolates CH77 (JN944909, B), CH106 (JN944897, B) and 247FV2 (C) were generously donated by Prof. George Shaw, University of Pennsylvania, Philadelphia, USA. Virus and Ad5-based regimen HIV-1 gene insert sequence homologies were determined using 'Align sequences protein blast' tool available at http://blast. ncbi.nlm.nih.gov/blast.cgi ( Table 2 ). CM235 and 97ZA012 isolates were cultured in 3 day phytohemagglutinin-treated PBMC followed by IL-2 (Roche Diagnostics, Lewes, East Sussex, UK; 20 units/ml). IIIB and ELI were cultured in H9 cell line. Viral titres were determined using the TZM-bl cell line [49] . Cell lines were obtained from the NIH AIDS Research and Reference Reagent Program.
Luciferase viruses
Two HIV-1-infectious molecular clones engineered to contain Renilla reniformis luciferase gene (LucR) (GenBank AF362549) were generously provided by Dr Ochsenbauer, University of Alabama, Birmingham, USA; NL-LucR.T2A and CH077.t-LucR.T2A. The construction of these from NL4-3 (M19921, subtype B) and CH077.t (JN944909, B), respectively, has been described [50, 51] . These viruses were applied to a sample subset to compare inhibition of CD8 þ T cells isolated directly from PBMC or following culture with CD3 þ / CD4 þ bispecific antibody.
CD4 R and CD8 R T cells PBMC were resuspended at 1-1.5 Â 10 6 /ml in RPMI/ 10% HIFCS/50 units IL-2 (R10/50) and 0.5 mg/ml CD3 þ /CD4 þ or CD3 þ /CD8 þ bispecific antibody for generation of CD8 þ or CD4 þ T cells, respectively [52] . Culture volumes were doubled at days 3 and 6 with R10/ 50 medium. Typical purities of 7-day cultures are 97 and 87% of CD3 þ T cells for CD4 þ and CD8 þ T cells, respectively [43] . Expanded CD8 þ T-cell memory phenotypes were assessed by flow cytometery. 
Viral inhibition assay
VIA, viral inhibition assay. 0.5 Â 10 6 autologous CD8 þ T cells in 1 ml R10/50 in 48 well plates. Half of the supernatant was replaced with R10/50 on days 3, 6 and 10. Day 13 supernatant p24 content was measured by ELISA (Perkin Elmer, Beaconsfield, Buckinghamshire, UK). CD8 þ T-cell-mediated inhibition was expressed as log 10 reduction in p24 content (pg/ml) of CD4 þ /CD8 þ cocultures compared with CD4 þ T cells alone. A positive inhibition threshold of p24 reduction more than 1.5 log was determined in previous studies from the distribution of inhibition observed in placebo and prevaccination trial volunteers [43, [53] [54] [55] [56] .
Comparison of antibody-expanded and directly-isolated CD8 R T cells LucR VIA experiments used expanded CD4 þ T cells cocultured with expanded CD8 þ T cells or CD8 þ T cells obtained by direct isolation from PBMC thawed one day prior to coculture and rested overnight in RPMI 20% HIFCS. CD8 þ T cells were negatively-selected using magnetic beads (Miltenyi-Biotec, Bergisch Gladbach, North Rhine-Westphalia, Germany).
IFN-g enzyme-linked immunospot assay
To identify which HIV-1 proteins were targeted by CD8 þ T cells tested in VIA, expanded CD8 þ T cells were washed three times in PBS and rested for 24 h in RPMI 20% HIFCS without IL-2 before IFN-g ELISpot, as previously described [47] using pools of overlapping 15mer peptides of HIV-1 consensus clade B Gag, Pol, Nef, Env, Vif, Vpu and Vpr (peptide sets from NIH AIDS Reagent Program). Expanded cell peptide responses were considered positive if they were twice wells without peptide (background) and background-subtracted responses were at least 50 spot-forming units (SFUs) per million cells.
Statistics
Linear regressions and significance values were generated using GraphPad Prism software, version 5.0 (GraphPad Software, San Diego, California, USA). Nonparametric Kruskal-Wallace test was used to determine significant differences within multiple data groups followed by Dunn's multiple comparison to identify differences between individual groups.
Results
Comparison of bispecific antibody-expanded and directly-isolated CD8 R T cells LucR VIA compared HIV-1 inhibitory abilities of expanded and directly isolated CD8 þ T cells from HIV-1-infected volunteers, selected with known ability to inhibit LucR viruses. From eight volunteers, between 0.8 and 2.8 million CD8 þ T cells (median 1.7 million) were recovered by direct isolation from 10 million cryopreserved PBMC. Bispecific antibody expansion achieved a median 4.7 and 4.9-fold (minimum 3-fold) increase from starting PBMC for CD4 þ and CD8 þ T cells, respectively (data not shown). Expanded CD8 þ T-cell phenotypes were predominantly central memory (CD45RO þ /CD27 þ ) with some effector memory (CD45RO þ /CD27 À ) ( Supplementary Fig. 1 , http:// links.lww.com/QAD/A917). There was a significant positive correlation between log 10 inhibition for expanded and isolated CD8 þ T cells (Fig. 1a , r 2 ¼ 0.72, P < 0.0001) with median inhibition of 1.250 and 1.248, respectively (Fig. 1b) . Therefore, antibodyexpanded and directly isolated CD8 þ T cells demonstrated similar HIV-1 inhibition. Subsequent data in this report utilized expanded cells.
Inhibition breadth of adenovirus serotype 5-based regimen vaccinees and HIV-1-infected volunteers CD8 þ T cells from 15 HIV-1-uninfected volunteers did not inhibit any HIV-1 isolate above the positive cut-off ( Fig. 1c ). Sixteen MRKAd5 vaccinees (26 weeks postfinal vaccination, visit 16) inhibited a median 2.0 isolates (range 0-5). Twelve VRC DNA/Ad5 vaccinees inhibited with slightly narrower breadth with median of 1 isolate at both 6 (visit 12) and 24 weeks (visit 14) postfinal vaccination (range 0-4). CD8 þ T cells from 16 antiretroviral-naive HIV-1-infected volunteers with pVL less than 10 000/ml, inhibited a median of three isolates (range 0-5) (Fig. 1c ). Within this group, there was no correlation between pVL and breadth of inhibition (r 2 ¼ 0.012, P ¼ 0.69, data not shown). Kruskal-Wallace analysis indicated a significant difference in inhibition breadth between the Ad5-based regimen vaccinees and HIV-1-infected volunteer groups (P ¼ 0.032). Dunn's multiple comparison identified inhibition breadth at both VRC DNA/Ad5 time-points to be significantly lower than HIV-1-infected volunteers (P < 0.05). There were no significant differences between other volunteer groups (P > 0.05).
Lack of inhibition with ALVAC/AIDSVAX regimen CD8 þ T cells from 21 RV135 volunteers 4 weeks postfinal vaccination did not inhibit isolates IIIB (clade B) and CM235 (AE) above the assay positive value (Fig. 1d) .
HIV-1 gene inserts of this regimen were derived from these two isolates. Other unmatched viruses were not tested. 69 and 56% of the HIV-1-infected volunteers inhibited IIIB and CM235 isolates, respectively (Fig. 1d ).
Inhibition of HIV-1 isolates elicited by adenovirus serotype 5-based regimens
The MRKAd5 and VRC DNA/Ad5 candidates were engineered with HIV-1 gene inserts derived from or with high sequence identities (!96% for Gag/Pol, 85-97% for Nef) to clade B HIV-1 isolate IIIB (Table 2 ) and this isolate was the most commonly inhibited with 69% MRKAd5 volunteers inhibiting (Fig. 1d ). 67% of VRC DNA/Ad5 volunteers inhibited this isolate at one or more of the two postvaccination time-points. The other IIIB  CH77  CH106  ELI  247Fv2  97ZA012  IIIB  CH77  CH106  ELI  247Fv2  97ZA012  IIIB  CH77  CH106  ELI  247Fv2  97ZA012  IIIB  CM235  IIIB  CH77  CH106  ELI  247Fv2  97ZA012 
Subject group Isolates inhibited per subject
Clade B and nonclade B isolate inhibition in a clade B infected cohort
The HIV-1-infected volunteers were from a predominantly clade B cohort (84% for UK, HIV sequence database at www.hiv.lanl.gov). The three clade B isolates were the most commonly inhibited with 69% of volunteers inhibiting isolates IIIB and CH77 and 64% inhibiting CH106 (Fig. 1d ). Within this lower pVL group, there were no correlations between pVL and log 10 magnitude of inhibition for any of these clade B isolates (r 2 0.001-0.024, P ¼ 0.56-0.91, data not shown). Inhibition of nonclade B isolates ELI, 247Fv2 and ZA97012 was less common at 25, 38 and 13% of volunteers, respectively (Fig. 1d ).
IFN-g enzyme-linked immunospot identified
HIV-1 genes targeted by expanded CD8 R T cells 56% of MRKAd5 volunteers (regimen containing only clade B HIV-1 Gag/Pol/Nef genes) responded to at least one HIV-1 peptide pool (median 1.0, range 0-3), and all responding volunteers targeted at least one Gag or Pol pool with two volunteers (13%) also responding to Nef ( Table 3 ). 42% of VRC DNA/Ad5 volunteers (regimen containing clade B Gag/Pol/Nef and multiclade Env genes) responded to at least one HIV-1 peptide pool (median 0, range 0-1) with responses restricted to Gag or Pol.
CD8 þ T cells from 81% of HIV-1-infected volunteers responded in ELISpot to at least one clade B HIV-1 peptide pool (median 1.0, range 0-6) with the predominant response being to Gag (63% of volunteers).
25-38% of volunteers responded to other pools.
Combining all volunteer groups, there was no correlation between ELISpot response magnitude (summed SFU) and VIA breadth (r 2 ¼ 0.003, P ¼ 0.72) ( Fig. 2a ). There was a significant correlation between the number of ELISpot pool responses and VIA breadth (r 2 ¼ 0.15, P ¼ 0.01) (Fig. 2b) .
Discussion
MRKAd5 and VRC DNA/Ad5 Ad5-based regimens although immunogenic, eliciting HIV-1-specific T cells detected by IFNg ELISpot and flow cytometry assays [10] [11] [12] , failed to protect against infection or reduce viremia [5] [6] [7] [8] . The present study demonstrated that CD8 þ T cells elicited by these Ad5-based regimens are directly antiviral, inhibiting HIV-1 replication in vitro although with limited inhibition breadth, HIV-1 IIIB being the most frequently inhibited followed by other clade B isolates ( Fig. 1c and d) . Vector encoded Gag and Pol genes for both regimens had high sequence identity (>96%, Table 2 ) to HIV-1 IIIB Gag and Pol genes, with these proteins being the predominant targets recognized in ELISpot (Table 3) , explaining the efficient inhibition of this isolate. HIV-1 isolate inhibition frequencies following these Ad5-based regimens can be summarized as vector insert sequence matched isolate IIIB more than vector insert clade matched isolates (clade B T/F isolates CH77 and CH106) more than nonclade B isolates.
No inhibition of vaccine insert matched isolates IIIB or CM235 was detected in ALVAC/AIDSVAX vaccinees, although these isolates were readily inhibited by HIV-1-infected volunteers (Fig. 1d ). This would be expected as this regimen induces minimal CD8 þ T-cell responses [15] , and a subsequent efficacy trial demonstrated a significant 31% protection from infection [9] was associated with humoral responses [16] .
HIV-1 inhibition breadth of antiretroviral-naive HIV-1-infected volunteers with pVL less than 10 000/ml was 1708 AIDS 2016, Vol 30 No 11 assessed as a benchmark to represent volunteers where CD8 þ T-cell-mediated control of HIV-1 replication may be expected [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Inhibition breadth was superior to that elicited by either Ad5-based regimen (Fig. 1c) but was significant only for the VRC DNA/Ad5 regimen. There was no significant difference between Ad5 regimens. These presumed clade B infected volunteers commonly inhibited the three clade B isolates; laboratory-adapted IIIB and T/F isolates CH77 and CH106. Nonclade B isolates were inhibited to a lesser extent (Fig. 1d ). IFNg ELISpot demonstrated CD8 þ T cells from HIV-1-infected volunteers primarily targeted Gag amongst other HIV-1 proteins ( Table 3 ).
The narrower breadth of vaccine-elicited inhibition compared with HIV-1-infected volunteers could be explained by a report [57] demonstrating that both MRKAd5 and VRC Ad5/DNA regimens elicit T-cell responses to far fewer HIV-1 epitopes than natural infection and that these epitopes were often clustered in highly variable regions. The finding that CD8 þ T cells from infected volunteers controlling viremia in vivo, can inhibit a range of HIV-1 isolates, including T/F viruses, demonstrates that inhibitory T cells can be elicited with sufficient breadth to recognize both intra-clade and interclade HIV-1 isolates and supports the development of regimens designed to elicit T cells. It would be desirable for vaccine candidates to induce CD8 þ T cells capable of inhibition breadth at least similar or superior to that seen in naturally controlled HIV-1 infection. At a minimum, such regimens could encode HIV-1 genes for the predominant clade circulating within geographic regions, with Gag and Pol being included because of greater sequence conservation of these genes. The present report demonstrated that Gag and Pol were the predominant HIV-1 proteins recognized by CD8 þ T cells in both Ad5 regimen vaccinees and HIV-1-infected volunteers. The correlation between the number of peptide pools recognized by CD8 þ T cells and breadth of VIA (Fig. 2b ) supports the strategy that T-cell-based vaccines should aim to increase the number of HIV-1 epitopes targeted by T cells, thereby potentially enhancing vaccine efficacy [58] .
The present report agrees with a report [59] describing inhibitory abilities of CD8 þ T cells isolated directly from PBMC from HIV-1-infected STEP vaccinees (MRKAd5) in which inhibition would be because of a combination of vaccination and natural infection. Inhibition breadth was narrow and inferior to chronically infected viremic controllers (pVL < 5000/ml). However, PBMC availability limited the number of isolates tested in the majority of vaccinees to 3 or 4. As blood volumes from multiple clinical trial time-points are limited, expansion of T cells would often be the only practical approach to assess inhibition breadth of multiple HIV-1 isolates on a consistent basis. One concern would be that T-cell expansion results in T-cell specificities that do not reflect those in vivo. The present report demonstrated that inhibition values of expanded and directly isolated CD8 þ T cells were almost identical ( Fig. 1a and b) , demonstrating antibody expansion is a valid approach for assessing CD8 þ T-cell-mediated HIV-1 inhibition. The expansion approach allows testing of at least 12 HIV-1 isolates and ELISpot analysis in parallel from a single frozen PBMC vial. The luciferase VIA under development uses fewer cells, allowing even more HIV-1 isolates to be tested [56] . Another report demonstrated the VRC DNA/Ad5
Vaccine-elicited CD8 R T-cell HIV-1 inhibition Hayes et al. 1709 regimen elicited inhibitory CD8 þ T cells, although the virus isolates tested only differed in Env sequence, being isogenic for other HIV-1 genes. Inhibition was associated with central and effector memory CD8 þ T cells expressing CD107a and MIP1b [60] . The present report demonstrated expanded CD8 þ T cells were of central and effector memory phenotypes ( Supplementary  Fig. 1 , http://links.lww.com/QAD/A917).
Present VIA and other immunogenicity data from phase I/II clinical trials [36] [37] [38] have demonstrated that Ad5-based regimens elicit T cells with limited breadth of recognition of HIV-1 isolates, and this may be a factor in the lack of efficacy demonstrated in subsequent trials. A full assessment of immunogenicity profiles elicited by candidate regimens in early phase trials, including inhibition breadth, allows development and selection of the most promising regimen combinations for further trials. The challenge for development of T-cell-based vaccine candidates is to elicit CD8 þ T cells with broader inhibition than MRKAd5 and VRC DNA/Ad5 regimens and at least as broad or superior to antiretroviralnaive HIV-1-infected volunteers. Approaches designed to enhance the breadth of vaccine-elicited T-cell responses have been proposed [58] . Although the benefit of eliciting CD8 þ T cells with inhibitory breadth equivalent to HIV-1-infected volunteers may be questionable, as such individuals usually progress to AIDS without treatment, the hope would be that eliciting such T cells prior to HIV-1 exposure would contain initial viral replication to prevent infection establishment or reduce viremia. Such a possibility has been demonstrated for SIV infection in which a replicating cytomegalovirus vector [31, 61] or a combination of yellow fever and Ad5 vectors [34] elicit potent SIV-specific CD8 þ T-cell responses and control of SIV replication in NHP. VIA can also characterize beneficial CD8 þ T-cell responses in infection, determining which HIV-1 genes and epitopes targeted are associated with control and informing on regimen design and has demonstrated the potential benefit of enhancing subdominant CD8 þ T-cell responses as part of cure strategies aimed at elimination of the latent viral reservoir in HIV-1-infected volunteers [62] . 
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